{"corpus_id":199418219,"paper_sha":"f4f597d850dc24d572b287b4b4df12d859132cc3","doi":"10.7150/THNO.34070","arxiv_id":null,"pmid":31534501,"pmcid":"6735385","mag_id":2968115401,"dblp_id":null,"acl_id":null,"title":"Tumor-derived DNA from pleural effusion supernatant as a promising alternative to tumor tissue in genomic profiling of advanced lung cancer","year":2019,"publication_date":"2019-07-28","venue":"Theranostics","journal":{"name":"Theranostics","pages":"5532 - 5541","volume":"9"},"journal_issn":null,"journal_title":null,"publication_types":["JournalArticle"],"pubmed_pub_types":["Journal Article","Research Support, Non-U.S. Gov't"],"s2_fields_of_study":["Medicine"],"reference_count":38,"citation_count":97,"influential_citation_count":6,"is_open_access":false,"arxiv_categories":null,"arxiv_license":null,"arxiv_journal_ref":null,"mesh_headings":[{"d":"Adult","mj":false,"ui":"D000328"},{"d":"Aged","mj":false,"ui":"D000368"},{"d":"Aged, 80 and over","mj":false,"ui":"D000369"},{"d":"DNA, Neoplasm","mj":false,"qs":[{"q":"genetics","mj":true,"ui":"Q000235"},{"q":"metabolism","mj":false,"ui":"Q000378"}],"ui":"D004273"},{"d":"Female","mj":false,"ui":"D005260"},{"d":"Gene Expression Profiling","mj":false,"ui":"D020869"},{"d":"Genomics","mj":false,"ui":"D023281"},{"d":"Humans","mj":false,"ui":"D006801"},{"d":"Lung Neoplasms","mj":false,"qs":[{"q":"genetics","mj":true,"ui":"Q000235"},{"q":"metabolism","mj":false,"ui":"Q000378"},{"q":"pathology","mj":false,"ui":"Q000473"}],"ui":"D008175"},{"d":"Male","mj":false,"ui":"D008297"},{"d":"Middle Aged","mj":false,"ui":"D008875"},{"d":"Pleural Effusion","mj":false,"qs":[{"q":"metabolism","mj":true,"ui":"Q000378"}],"ui":"D010996"}],"chemicals":[{"n":"DNA, Neoplasm","ui":"D004273","reg":"0"}],"comments_corrections":null,"source_flags":5,"s2_open_access_pdf_url":null,"s2_open_access_landing_url":null,"s2_open_access_license":null,"s2_open_access_status":null,"pmc_open_access_pdf_url":null,"pmc_open_access_landing_url":null,"pmc_open_access_license":null,"pmc_open_access_status":null,"unpaywall_open_access_pdf_url":null,"unpaywall_open_access_landing_url":null,"unpaywall_open_access_license":null,"unpaywall_open_access_status":null,"abstract":"Pleural effusion (PE) is commonly observed in advanced lung cancer and was suggested to contain both cell-free tumor DNA and tumor cells. Molecular profiling of PE represents a minimally invasive approach of detecting tumor driver mutations for clinical decision making, especially when tumor tissues are not available. The objective of this study is to investigate the efficacy and precision of detecting gene alterations in PE samples to address the feasibility in clinical use. Methods: Sixty-three metastatic lung cancer patients with (n=30, cohort 1) or without (n=33, cohort 2) matched tumor tissues were enrolled in this study. PE and plasma samples of each patient were collected simultaneously. Supernatant and cell precipitate of PE were processed separately to extract cfDNA (PE-cfDNA) and sediment DNA (sDNA). All samples were subjected to targeted next-generation sequencing (NGS) of 416 cancer-related genes. Results: PE supernatants contain more abundant tumor DNA than PE sediments and plasma samples, suggested by higher mutant allele frequencies (MAF) and elevated mutation detection rate in PE-cfDNA (98.4% vs. 90.5% in PE sDNA vs. 87% in plasma cfDNA). In Cohort 1 with matched tumor tissue, tumor mutational burden (TMB) of PE-cfDNA was similar as tumor tissues (6.4 vs. 5.6), but significantly higher than PE sDNA (median TMB: 3.3) and plasma cfDNA (median TMB: 3.4). Ninety-three percent (27 out of 29) of tissue-determined driver mutations were detected in PE-cfDNA, including alterations in ALK, BRAF, EGFR, ERBB2, KRAS, NF1, PIK3CA, and RET, while only 62% were captured in plasma cfDNA. PE-cfDNA also has the highest detection rate of EGFR driver mutations in the full cohort (71% vs. 68% in PE sDNA vs. 59% in plasma cfDNA). Mutation detection from cytological negative and hemorrhagic PE is challenging. Comparatively, PE-cfDNA demonstrated absolute superiority than PE sDNA in such a scenario, suggesting that it is an independent source of tumor DNA and therefore less influenced by the abundance of tumor cells. Conclusion: Genomic profiling of PE-cfDNA offers an alternative, and potentially more meticulous approach in assessing tumor genomics in advanced lung cancer when tumor tissue is not available. Our data further demonstrate that in hemorrhagic or cytologically negative PE samples, PE-cfDNA has higher mutation detection sensitivity than sDNA and plasma cfDNA, and therefore is a more reliable source for genetic testing.","claims":[{"public_id":"cl_6e4818686b2acb904826f712ad8b1ab9","status":"active","text":"In hemorrhagic or cytologically negative pleural effusion samples, pleural effusion supernatant-derived cell-free DNA detects mutations more sensitively than pleural effusion sediment DNA and plasma cell-free DNA and functions as an independent source of tumor DNA.","confidence":0.96,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_6e4818686b2acb904826f712ad8b1ab9"},{"public_id":"cl_600e8cc5563ae81cae33e4d644461148","status":"active","text":"Pleural effusion supernatant-derived cell-free DNA contains more abundant tumor DNA than pleural effusion sediment DNA and plasma cell-free DNA, as reflected by higher mutant allele frequencies and mutation detection rates.","confidence":0.98,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_600e8cc5563ae81cae33e4d644461148"},{"public_id":"cl_e6a7e543024fc061877131126407673a","status":"active","text":"Pleural effusion supernatant-derived cell-free DNA detects 93% of tissue-determined driver mutations, including ALK, BRAF, EGFR, ERBB2, KRAS, NF1, PIK3CA, and RET alterations, whereas plasma cell-free DNA detects 62%.","confidence":0.97,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_e6a7e543024fc061877131126407673a"},{"public_id":"cl_f24263ea65c6494dadb826abb0e1de2f","status":"active","text":"Pleural effusion supernatant-derived cell-free DNA has the highest EGFR driver mutation detection rate in the full cohort, exceeding pleural effusion sediment DNA and plasma cell-free DNA.","confidence":0.95,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_f24263ea65c6494dadb826abb0e1de2f"},{"public_id":"cl_b9617e1cb0fa0d6deacde1a7511b19cd","status":"active","text":"Pleural effusion supernatant-derived cell-free DNA shows tumor mutational burden similar to matched tumor tissue and higher than pleural effusion sediment DNA and plasma cell-free DNA.","confidence":0.96,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_b9617e1cb0fa0d6deacde1a7511b19cd"}],"concepts":[{"public_id":"co_04bcf302c02441deb51ca3545fa609f5","status":"active","name":"EGFR driver mutations","description":"Activating or clinically relevant mutations in the EGFR gene.","types":["genetic alteration"],"aliases":["EGFR alterations"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_04bcf302c02441deb51ca3545fa609f5"},{"public_id":"co_07958717e9bf85eff25b3bb9f1bb2a5d","status":"active","name":"plasma cell-free DNA","description":"Cell-free DNA extracted from blood plasma for mutation analysis.","types":["biomarker","specimen"],"aliases":["plasma cfDNA"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_07958717e9bf85eff25b3bb9f1bb2a5d"},{"public_id":"co_16abf8ebdb0d0487823e7c8120e2def9","status":"active","name":"cytologically negative pleural effusion samples","description":"Pleural effusion samples in which cytology does not detect tumor cells.","types":["specimen"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_16abf8ebdb0d0487823e7c8120e2def9"},{"public_id":"co_2cb5b4814a68812588faebd6615012a3","status":"active","name":"hemorrhagic pleural effusion samples","description":"Pleural effusion samples containing blood contamination.","types":["specimen"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_2cb5b4814a68812588faebd6615012a3"},{"public_id":"co_4842913a32b50fe43574c6a4453947db","status":"active","name":"pleural effusion sediment DNA","description":"DNA extracted from the cellular sediment or cell precipitate of pleural effusion samples.","types":["specimen","biomarker"],"aliases":["sDNA"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_4842913a32b50fe43574c6a4453947db"},{"public_id":"co_4e40e20f48e473049a2313fe8cc31369","status":"active","name":"matched tumor tissue","description":"Tumor tissue from the same patient used as a reference sample for genomic comparison.","types":["reference sample","specimen"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_4e40e20f48e473049a2313fe8cc31369"},{"public_id":"co_8d4f416867fa86079ef8433662e7de9d","status":"active","name":"advanced lung cancer","description":"Lung cancer at an advanced metastatic stage.","types":["disease"],"aliases":["metastatic lung cancer"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_8d4f416867fa86079ef8433662e7de9d"},{"public_id":"co_9aa2f13ff8103a6f97e3ef24021d7ac1","status":"active","name":"tissue-determined driver mutations","description":"Driver gene alterations identified in tumor tissue and used as the comparison set for liquid-biopsy detection.","types":["genetic alteration","reference set"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_9aa2f13ff8103a6f97e3ef24021d7ac1"},{"public_id":"co_b9d365757f9a6abee6705e90101dac13","status":"active","name":"pleural effusion supernatant-derived cell-free DNA","description":"Cell-free DNA extracted from the supernatant fraction of pleural effusion samples.","types":["biomarker","specimen"],"aliases":["PE-cfDNA"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_b9d365757f9a6abee6705e90101dac13"},{"public_id":"co_ce238aed587f1dfda0e95eec325995d9","status":"active","name":"targeted next-generation sequencing","description":"A sequencing approach that interrogates a predefined panel of genes for genomic alterations.","types":["method"],"aliases":["targeted NGS"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_ce238aed587f1dfda0e95eec325995d9"},{"public_id":"co_ead909332b0da683bf04e8aa14dcef90","status":"active","name":"driver mutations","description":"Genetic alterations that contribute to cancer development and are relevant for clinical profiling.","types":["genetic alteration"],"aliases":["gene alterations"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_ead909332b0da683bf04e8aa14dcef90"},{"public_id":"co_f27c2a6ae7595dbfec1979048e5dd0e6","status":"active","name":"tumor mutational burden","description":"The number of somatic mutations present in a tumor DNA sample.","types":["measure"],"aliases":["TMB"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_f27c2a6ae7595dbfec1979048e5dd0e6"}],"external_ids":{"DOI":"10.7150/THNO.34070","ArXiv":null,"PubMed":31534501,"PubMedCentral":"6735385","MAG":2968115401,"DBLP":null,"ACL":null},"open_access":{"is_open_access":false,"pdf_url":null,"landing_url":"https://sah.borca.ai/papers/199418219","source":null,"pdf_url_source":null,"license":null,"reason":"pdf_url_not_indexed"},"reference_availability":{"status":"available","references_indexed":true,"full_text_available":false,"full_text_source":null,"count_basis":"semantic_scholar_metadata","extraction_status":"not_applicable","reason":null},"source":{"provider":"episteme2","base_corpus":"semantic_scholar_dump","freshness_mode":"unknown","basis":["semantic_scholar_metadata","postgres_metadata"],"limits":["paper metadata is based on indexed upstream scholarly datasets","claims and concepts are available only for extracted papers","absence of claims or concepts means no extracted graph data is available in this response"],"status":"available","degraded":false,"degraded_reasons":[],"diagnostics":{"status":"available","degraded":false,"degraded_reasons":[],"metadata_status":"available","graph_status":"available","abstract_status":"available"},"source_flags":5},"paper_id":632096,"paper_uid":"1a768a89-c962-42e6-bd9d-ef14ce7ecdb3","canonical_identity":{"paper_id":632096,"paper_uid":"1a768a89-c962-42e6-bd9d-ef14ce7ecdb3","identity_status":"available","lookup_basis":"semantic_scholar_external_id","compatibility_path":"corpus_id"},"url":"https://sah.borca.ai/papers/199418219"}